Compare AUDC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUDC | CGEN |
|---|---|---|
| Founded | 1992 | 1993 |
| Country | Israel | Israel |
| Employees | N/A | 75 |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.9M | 256.2M |
| IPO Year | 2000 | 2001 |
| Metric | AUDC | CGEN |
|---|---|---|
| Price | $10.14 | $2.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.50 | $5.00 |
| AVG Volume (30 Days) | 83.9K | ★ 555.5K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.24 | N/A |
| Revenue Next Year | $2.18 | $75.09 |
| P/E Ratio | $23.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.95 | $1.23 |
| 52 Week High | $11.48 | $3.24 |
| Indicator | AUDC | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 71.85 | 51.91 |
| Support Level | $8.45 | $1.45 |
| Resistance Level | $10.47 | $3.24 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 87.70 | 15.11 |
AudioCodes Ltd provides voice communications solutions for enterprises, contact centers, and service providers, including voice infrastructure, cloud-based platforms, and Voice AI applications. Its AudioCodes Live Platform is a cloud-based service delivery platform that enables provisioning, management, and operation of voice and AI-based communication services, including PSTN connectivity and integration with platforms such as Microsoft Teams, Webex Calling, and Zoom Phone. The company's solutions are organized into three layers: voice infrastructure and devices, cloud-based platforms, and Voice AI applications for contact center and productivity use cases. It also offers management tools such as One Voice Operations Center (OVOC), Device Manager, and AudioCodes Routing Manager (ARM).
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.